Cyclerion Therapeutics,Inc. (CYCN)
NASDAQ:CYCN
US Market

Cyclerion Therapeutics Income Statement

144 Followers

Cyclerion Therapeutics Income Statement

Last quarter (Q3 2022), Cyclerion Therapeutics's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q3, Cyclerion Therapeutics's net income was $-10.50M. See Cyclerion Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 479.00K$ 3.32M$ 2.30M$ 4.51M$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 51.84M$ 57.63M$ 85.23M$ 129.54M$ 115.25M$ 93.92M
Operating Income
$ -51.36M$ -54.31M$ -82.93M$ -125.04M$ -115.25M$ -93.92M
Net Non Operating Interest Income Expense
$ 161.00K$ -16.00K$ 588.00K$ 2.03M$ 0.00-
Other Income Expense
$ 3.56M$ 2.68M$ 4.54M---
Pretax Income
$ -47.64M$ -51.65M$ -77.80M$ -123.01M$ -115.25M$ -93.92M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -47.64M$ -51.65M$ -77.80M$ -123.01M$ -115.25M$ -93.92M
Basic EPS
$ -1.09$ -1.32$ -2.56$ -4.49$ -4.22$ -3.44
Diluted EPS
$ -1.09$ -1.32$ -2.56$ -4.49$ -4.22$ -3.44
Basic Average Shares
$ 173.76M$ 39.14M$ 30.40M$ 27.38M$ 27.30M$ 27.30M
Diluted Average Shares
$ 173.76M$ 39.14M$ 30.40M$ 27.38M$ 27.30M$ 27.30M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 51.84M$ 57.63M$ 85.23M$ 129.54M$ 115.25M$ 93.92M
Net Income From Continuing And Discontinued Operation
$ -47.64M$ -51.65M$ -77.80M$ -123.01M$ -115.25M$ -93.92M
Normalized Income
$ -51.20M$ -54.33M$ -82.35M$ -123.01M$ -115.25M$ -93.92M
Interest Expense
$ 1.00K$ 16.00K----
EBIT
$ -48.68M$ -51.63M$ -82.93M$ -125.04M$ -115.25M$ -93.92M
EBITDA
$ -48.57M$ -51.16M$ -80.64M$ -122.34M$ -113.72M$ -92.18M
Currency in USD

Cyclerion Therapeutics Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis